CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 07:42:47 2024-06-18 EDT | ||
| 18.14 EUR | -2.42% |
|
| Current month | +15.47% | ||
| 1 month | +20.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-18 | 18.14 | -2.42% |
| 24-06-17 | 18.59 | -3.33% |
| 24-06-14 | 19.23 | +1.96% |
| 24-06-13 | 18.86 | +2.00% |
| 24-06-12 | 18.49 | -2.79% |
Delayed Quote Deutsche Boerse AG
Last update June 18, 2024 at 07:42 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GF6 |
| ISIN | DE000VU8GF65 |
| Date issued | 2023-06-13 |
| Strike | 280 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 8.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.33 € |
|---|---|
| Lowest since issue | 7.26 € |
| Spread | 0.04 € |
| Spread % | 0.22% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.7
USD
Average target price
463.4
USD
Spread / Average Target
-2.17%
- Stock Market
- Certificates
- Certificat
